Nevertheless, what does appear to be a valid conclusion is that if there is a shift from PKM1 to PKM2, the lowered activity of PKM2 as compared to PKM1 does not provide CCRCC tumor cells with a proliferative advantage by forcing a buildup of metabolites that can be used to synthesize key biomolecules such as nucleotides and amino acids. The gene discussed is PKM; the disease is neoplasm.